Trial · NCT03753919
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival Rate at 6 Months | Throughout the study period, up to 6 months from start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| PRIMARY | Overall Survival Rate at 6 Months | Throughout the trial period, up to 6 months from first dose of treatment. | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Overall Survival, Median | Throughout the trial period, with a following up to 4 years from the start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | months | MEDIAN |
| SECONDARY | Overall Survival Rate at 18 Months | Throughout the trial period, up to 18 months from first dose of treatment. | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Progression-free Survival (PFS), Median | Throughout the trial period, a median follow-up period 14 months from the start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | months | MEDIAN |
| SECONDARY | Progression-free Survival Rate at 18 Months | Throughout the study period, up to 18 months from start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Overall Response Rate (ORR) | Through study completion, average 1 year | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Overall Response (OR) Best Response According to RECIST 1.1 | Throughout the trial period, with a following up to 4 years from the start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Overall Response (OR) Best Response According irRecist Criteria | Throughout the trial period, with a following up to 4 years from the start of treatment | Patients with progressive, refractory advanced thyroid carcinoma | percentage of patients | NUMBER |
| SECONDARY | Duration of Response (DoR) Median RECIST 1.1 Criteria | Through study period, assessed up to 4 years | Patients with progressive, refractory advanced thyroid carcinoma | months | MEDIAN |
| SECONDARY | Duration of Response (DoR) Median irRECIST Criteria | Through study period, assessed up to 4 years | Patients with progressive, refractory advanced thyroid carcinoma | months | MEDIAN |
| SECONDARY | Percentage of Participants With Treatment-Related Adverse Events (TRAEs) | Throughout the study period, from start treatment up 90 days after the last dose, up to 5 years. | Safety Analysis Set will include all subjects who were allocated and received at least one dose of the study drug and had at least one post-baseline safety evaluation (week 12). This will be the analysis set for all safety evaluations. | percentage of patients | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03753919/outcomes